| 2025-11-10 |
详情>>
股本变动：
变动后总股本9530.02万股
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-5.12美元,归母净利润-4.51亿美元,同比去年增长-37.1%
|
| 2025-10-16 |
详情>>
内部人交易：
Kulkarni Samarth共交易2笔
|
| 2025-08-04 |
详情>>
业绩披露：
2025年中报每股收益-3.98美元,归母净利润-3.45亿美元,同比去年增长-41.79%
|
| 2025-05-06 |
详情>>
业绩披露：
2025年一季报每股收益-1.58美元,归母净利润-1.36亿美元,同比去年增长-16.64%
|
| 2025-04-16 |
股东大会：
将于2025-06-05召开股东大会
会议内容 ▼▲
- 1.Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2024;
2.Approval of the appropriation of financial results;
3.Discharge of the members of the Board of Directors and the Executive Committee;
4.Election or re-election of eleven members to the Board of Directors, including the Chairman of the Board of Directors, each for a term extending until the completion of the 2026 annual general meeting of shareholders (Proposals 4.a-4.k);
5.Election or re-election of the members of the Compensation Committee (Proposals 5.a-5.d);
6.Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2024 Compensation Report (Proposals 6.a-6.f);
7.Non-binding advisory vote on the compensation paid to the Company’s named executive officers under U.S. securities law requirements;
8.Approval of an increase in the maximum size of the Board of Directors;
9.Re-election of the independent voting rights representative;
10.Re-election of the auditors (Proposal 10);
11.Transact any other business that may properly come before the 2025 Annual General Meeting or any adjournment or postponement thereof (Proposal 11).
|
| 2025-02-11 |
详情>>
业绩披露：
2024年年报每股收益-4.34美元,归母净利润-3.66亿美元,同比去年增长-138.43%
|
| 2025-02-11 |
详情>>
业绩披露：
2022年年报每股收益-8.36美元,归母净利润-6.5亿美元,同比去年增长-272.16%
|
| 2024-11-05 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-3.92美元,归母净利润-3.29亿美元,同比去年增长-35.39%
|
| 2024-08-05 |
详情>>
业绩披露：
2023年中报每股收益-1.66美元,归母净利润-1.31亿美元,同比去年增长64.17%
|
| 2024-08-05 |
详情>>
业绩披露：
2024年中报每股收益-2.92美元,归母净利润-2.43亿美元,同比去年增长-85.77%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-1.43美元,归母净利润-1.17亿美元,同比去年增长-119.71%
|
| 2024-04-09 |
股东大会：
将于2024-05-30召开股东大会
会议内容 ▼▲
- 1.Approval of the Swiss Management Report, the Consolidated Financial Statements and the Statutory Financial Statements of the Company for the year ended December 31, 2023.
2.Approval of the Appropriation of Financial Results.
3.Discharge of the Members of the Board of Directors and the Executive Committee.
4.Election or Re-election of the Members to the Board of Directors and the Chairman.
5.Re-election of the Members of the Compensation Committee.
6.Approval of the Compensation for the Board of Directors and the Executive Committee and Non-Binding Advisory Vote on the 2023 Compensation Report.
7.Non-Binding Advisory Vote on the Compensation Paid to the Company’s Named Executive Officers under U.S. Securities Law Requirements.
8.Approval of an Increase of the Conditional Share Capital for Employee Equity Plans.
9.Approval of an Amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.
10.Approval of Amendments to the Articles of Association to Facilitate the Use of Equity Compensation and Pension Benefits Programs Consistent with Current Market Practices.
11.Approval of an Increase and Certain Adjustments to the Company’s Capital Band.
12.Re-election of the Independent Voting Rights Representative.
13.Re-election of the Auditors.
14.Transact any Other Business that may Properly Come Before the 2024 Annual General Meeting or any Adjournment or Postponement thereof.
|
| 2024-02-21 |
详情>>
业绩披露：
2023年年报每股收益-1.94美元,归母净利润-1.54亿美元,同比去年增长76.37%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-3.07美元,归母净利润-2.43亿美元,同比去年增长54.97%
|
| 2023-10-31 |
复牌提示：
2023-10-31 06:55:00 停牌，复牌日期 2023-10-31 18:30:00
|
| 2023-04-26 |
股东大会：
将于2023-06-08召开股东大会
会议内容 ▼▲
- 1.Approval of the Swiss management report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2022.
2.Approval of the appropriation of financial results.
3.Discharge of the members of the Board of Directors and Executive Committee.
4.Re-election of the members to the Board of Directors.
5.Election or re-election of the members of the Compensation Committee.
6.Approval of the compensation for the Board of Directors and the Executive Committee and non-binding advisory vote on the 2022 Compensation Report.
7.Non-binding advisory vote to approve the compensation paid to the Company’s named executive officers under U.S. securities law requirements.
8.Approval of a capital band.
9.Approval of an increase in the conditional share capital for employee equity plans.
10.Approval of an amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.
11.Approval of a reduction in the maximum size of the Board of Directors.
12.Approval of amendments to the Articles of Association to reflect revised Swiss corporate law and other changes.
13.Re-election of the independent voting rights representative.
14.Re-election of the auditors.
15.Transact any other business that may properly come before the 2023 Annual General Meeting or any adjournment or postponement thereof.
|
| 2022-04-25 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.The approval of the Swiss statutory annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2021
2.The approval of the appropriation of financial results
3.The discharge of the members of the Board of Directors and the Executive Committee
4.The re-election of nine directors to our Board of Directors, including the chairman of the Board of Directors, each for a term extending until the completion of the 2023 annual general meeting of shareholders
5.The re-election of the members of the Compensation Committee of the Board of Directors
6.The approval of the compensation for the Board of Directors and the members of the Executive Committee
7.The non-binding advisory vote to approve the compensation paid to the Company’s named executive officers under U.S. securities law requirements
8.The non-binding advisory vote on the frequency of future shareholder advisory votes on the compensation paid to the Company’s named executive officers under U.S. securities law requirements
9.The approval of increasing the maximum size of the Board of Directors
10.The approval of an adjustment to the maximum number of authorized share capital and extending the date by which the Board of Directors may increase the share capital
11.The approval of an adjustment to the conditional share capital for the conversion of bonds and similar debt instruments
12.The approval of an increase in the conditional share capital for employee equity plans
13.The approval of an amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan
14.The re-election of the independent voting rights representative
15.The re-election of Ernst & Young AG as our statutory auditor for the term of office of one year and the re-election of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022
16.The transaction of any other business that may properly come before the 2022 Annual General Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-28 |
股东大会：
将于2021-06-10召开股东大会
会议内容 ▼▲
- 1.The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2020.
2.The approval of the appropriation of financial results.
3.The discharge of the members of the Board of Directors and Executive Committee.
4.The election and re-election of the members to the Board of Directors.
5.The re-election of the members of the Compensation Committee.
6.The approval of the compensation for the Board of Directors and the Executive Committee.6.a Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2021 Annual General Meeting to the 2022 annual general meeting of shareholders.6.b Binding vote on equity for members of the Board of Directors from the 2021 Annual General Meeting to the 2022 annual general meeting of shareholders.6.c Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2021 to June 30, 2022.6.d Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2021.6.e Binding vote on equity for members of the Executive Committee from the 2021 Annual General Meeting to the 2022 annual general meeting of shareholders.
7.The approval of an increase in the Conditional Share Capital for Employee Equity Plans.
8.The approval of increasing the maximum size of the Board of Directors.
9.The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase the share capital.
10.The re-election of the independent voting rights representative.
11.The re-election of the auditors.
12.The transaction of any other business that may properly come before the 2021 Annual General Meeting or any adjournment or postponement thereof.
|
| 2020-04-24 |
股东大会：
将于2020-06-11召开股东大会
会议内容 ▼▲
- 1.The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2019.
2.The approval of the appropriation of financial results.
3.The discharge of the members of the Board of Directors and Executive Committee.
4.The election and re-election of the members to the Board of Directors.
5.The election and re-election of the members of the Compensation Committee.
6.The approval of the compensation for the Board of Directors and the Executive Committee.
7.The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.
8.The approval of an Amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.
9.The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase the share capital.
10.The re-election of the independent voting rights representative.
11.The re-election of the auditors.
12.The transaction of any other business that may properly come before the 2020 Annual General Meeting or any adjournment or postponement thereof.
|
| 2019-04-30 |
股东大会：
将于2019-06-11召开股东大会
会议内容 ▼▲
- 1.The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2018.
2.The approval of the appropriation of financial results.
3.The discharge of the members of the Board of Directors and Executive Committee.
4.The election and re-election of the members to the Board of Directors.
5.The election and re-election of the members of the Compensation Committee.
6.The approval of the compensation for the Board of Directors and the Executive Committee.
7.Non-binding advisory vote to approve the compensation paid to the Company’s named executive officers under U.S. securities law requirements.
8.Non-binding advisory vote on the frequency of future shareholder advisory votes on the compensation paid to the Company’s named executive officers under U.S. securities law requirements.
9.The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.
10.The approval of an Amendment to the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.
11.The approval of amending and restating art. 3a of the Articles of Association.
12.The approval of amending and restating art. 4 of the Articles of Association.
13.The approval of amending and restating art. 16 of the Articles of Association.
14.The approval of amending and restating art. 17 of the Articles of Association.
15.The approval of amending and restating art. 41 of the Articles of Association.
16.The re-election of the independent voting rights representative.
17.The election of the auditors.
18.The transaction of any other business that may properly come before the 2019 Annual General Meeting or any adjournment or postponement thereof.
|
| 2018-04-18 |
股东大会：
将于2018-05-30召开股东大会
会议内容 ▼▲
- 1.The approval of the Annual Report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2017;
2.The approval of the appropriation of financial results;
3.The discharge of the members of the Board of Directors and the Executive Committee ;
4.The election and re-election of eight directors to our Board of Directors, including the chairman of the Board of Directors, each for a term extending until the completion of the 2019 annual general meeting of shareholders;
5.The re-election of the members of the Compensation Committee of the Board of Directors ;
6.The approval of the compensation for the Board of Directors and the members of the Executive Committee ;
7.The approval of an increase in the Conditional Share Capital for Employee Benefit Plans ;
8.The approval of the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan ;
9.The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase authorized share capital ;
10.The re-election of the independent voting rights representative ;
11.The re-election of Ernst & Young AG as our statutory auditor for the term of office of one year and the re-election of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018 ;
12.The transaction of any other business that may properly come before the 2018 Annual General Meeting or any adjournment or postponement thereof .
|
| 2017-04-18 |
股东大会：
将于2017-05-31召开股东大会
会议内容 ▼▲
- 1.The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2016.
2.The approval of the appropriation of financial results.
3.The discharge of the members of the Board of Directors and Executive Committee.
4.The re-election of the members to the Board of Directors.
5.The re-election of the members of the Compensation Committee.
6.The approval of the compensation for the Board of Directors and the Executive Committee.
7.The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.
8.The approval of the Amended and Restated CRISPR Therapeutics AG 2016 Stock Option and Incentive Plan.
9.The re-election of the independent voting rights representative.
10.The re-election of the auditors.
11.The approval of the change of the registered office
12.The transaction of any other business that may properly come before the 2017 Annual General Meeting or any adjournment or postponement thereof.
|